IS7057A - Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni - Google Patents

Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni

Info

Publication number
IS7057A
IS7057A IS7057A IS7057A IS7057A IS 7057 A IS7057 A IS 7057A IS 7057 A IS7057 A IS 7057A IS 7057 A IS7057 A IS 7057A IS 7057 A IS7057 A IS 7057A
Authority
IS
Iceland
Prior art keywords
ethoxy
phenyl
methanesulfonylloxyphenyl
sulonyl
butoxycarbonylaminophenyl
Prior art date
Application number
IS7057A
Other languages
English (en)
Inventor
Öhman Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7057A publication Critical patent/IS7057A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS7057A 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni IS7057A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001036 WO2002100413A1 (en) 2001-06-01 2002-05-30 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA

Publications (1)

Publication Number Publication Date
IS7057A true IS7057A (is) 2003-11-28

Family

ID=20284364

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7057A IS7057A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni

Country Status (21)

Country Link
US (1) US20040157927A1 (is)
EP (1) EP1399166A1 (is)
JP (1) JP2004532891A (is)
KR (1) KR20040007624A (is)
CN (1) CN1250226C (is)
BR (1) BR0210127A (is)
CA (1) CA2448763A1 (is)
CO (1) CO5540382A2 (is)
CZ (1) CZ20033235A3 (is)
EE (1) EE200300583A (is)
HU (1) HUP0401613A3 (is)
IL (1) IL159035A0 (is)
IS (1) IS7057A (is)
MX (1) MXPA03011010A (is)
NO (1) NO20035235D0 (is)
PL (1) PL367890A1 (is)
RU (1) RU2003136157A (is)
SE (1) SE0101982D0 (is)
SK (1) SK14722003A3 (is)
WO (1) WO2002100413A1 (is)
ZA (1) ZA200309263B (is)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs

Also Published As

Publication number Publication date
ZA200309263B (en) 2005-03-11
CZ20033235A3 (cs) 2004-12-15
NO20035235D0 (no) 2003-11-25
HUP0401613A3 (en) 2007-11-28
RU2003136157A (ru) 2005-05-20
MXPA03011010A (es) 2004-02-27
EE200300583A (et) 2004-02-16
EP1399166A1 (en) 2004-03-24
JP2004532891A (ja) 2004-10-28
SK14722003A3 (sk) 2004-08-03
US20040157927A1 (en) 2004-08-12
PL367890A1 (en) 2005-03-07
CN1250226C (zh) 2006-04-12
IL159035A0 (en) 2004-05-12
BR0210127A (pt) 2004-06-08
SE0101982D0 (sv) 2001-06-01
WO2002100413A1 (en) 2002-12-19
CN1537008A (zh) 2004-10-13
CA2448763A1 (en) 2002-12-19
KR20040007624A (ko) 2004-01-24
HUP0401613A2 (hu) 2004-11-29
CO5540382A2 (es) 2005-07-29

Similar Documents

Publication Publication Date Title
LU92025I2 (fr) Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
SI1667964T1 (sl) 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
NO20022591D0 (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
IS6400A (is) Kristallað form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýlfenýl}etoxý)fenýl]própanónsýra
NO2014011I2 (no) Vortioksetin eller et farmasøytisk akseptabelt syreaddisjonssalt dera
DK1144368T5 (da) Acetyleniske alfa-aminosyrebaserede sulfonamid-hydroxamsyre-TACE-inhibitorer
NO20003069D0 (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
NO20023379L (no) Farmasöytisk preparat omfattende premetrexed sammen med monotioglycerol-L-cystein eller tioglykolsyre
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
IS7056A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
DE602004028500D1 (de) 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
NO20024481D0 (no) Difluorbutyrsyre metalloproteaseinhibitorer
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
EE200300583A (et) Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja sulfonüüluureat
SE0101980D0 (sv) Pharmaceutical combination
NO20013681D0 (no) Acetyleniske heteroarylsulfonamid- og - fosfinsyreamidhydroksamsyre TACE-inhibitorer
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
ITBS20000022A0 (it) Composizione per uso topico a base di acido linoleico e/o lipoico
ITMI20042092A1 (it) Metodo per l'allestimento di pareti di ambienti e ambienti cosi' ottenuti